1. Home
  2. SUNS vs LUNG Comparison

SUNS vs LUNG Comparison

Compare SUNS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrise Realty Trust Inc.

SUNS

Sunrise Realty Trust Inc.

SELL

Current Price

$6.46

Market Cap

108.7M

Sector

Real Estate

ML Signal

SELL

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

SELL

Current Price

$1.85

Market Cap

97.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SUNS
LUNG
Founded
2023
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Industrial Specialties
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.7M
97.1M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
SUNS
LUNG
Price
$6.46
$1.85
Analyst Decision
Buy
Buy
Analyst Count
4
5
Target Price
★ $10.50
$3.40
AVG Volume (30 Days)
102.1K
★ 261.6K
Earning Date
11-12-2026
10-27-2026
Dividend Yield
★ 18.90%
N/A
EPS Growth
N/A
★ 7.64
EPS
★ 0.54
N/A
Revenue
$21,571,434.00
★ $90,497,000.00
Revenue This Year
$89.71
$0.06
Revenue Next Year
$11.95
$8.58
P/E Ratio
$11.76
★ N/A
Revenue Growth
★ 102.96
8.01
52 Week Low
$5.77
$1.13
52 Week High
$10.45
$2.89

Technical Indicators

Market Signals
Indicator
SUNS
LUNG
Relative Strength Index (RSI) 44.81 47.11
Support Level $5.77 $1.20
Resistance Level $7.90 $2.12
Average True Range (ATR) 0.29 0.11
MACD 0.03 -0.00
Stochastic Oscillator 45.58 51.79

Price Performance

Historical Comparison
SUNS
LUNG

About SUNS Sunrise Realty Trust Inc.

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: